This protocol allows CML and Ph+ ALL subjects who are resistant to or intolerant of imatinib
mesylate, to potentially benefit from dasatinib. It is intended to provide patients with
access to dasatinib while awaiting reimbursement decision in Korea and it will also provide
additional data on the safety of dasatinib in Korean population